Peptide Drugs for Alzheimer’s Disease Treatment

  • Novel peptide reduces amyloid precursor protein cleavage and Aβ plaque formation in the brain.


A method for the treatment of Alzheimer’s disease by administering a novel peptide that prevents Aβ-plaque accumulation in the brain.

Technology Description

Alzheimer’s disease is characterized by the accumulation of amyloid beta (Aβ) peptides in the brain. Aβ plaque is generated by the cleavage of amyloid precursor protein (APP), a transmembrane protein. This technology reduces or eliminates APP cleavage by using a novel peptide derived from Zika virus. Blocking APP cleavage results in the reduction of Aβ plaque formation. Overall, the peptide can be used to develop novel therapeutics for Alzheimer’s disease.

Contact Information

Name: Arpi Siyahian


Phone: 402-472-1783